Biomarkers of kidney disease
https://libcat.nshealth.ca/en/permalink/provcat31569
edited by Charles L. Edelstein.
(2nd ed.)
--Amsterdam, Netherlands:
Elsevier
, c2017.
- Available Online
- View e-Book
- Access
- Registration required for PDF access.
- Location
- Online
- Available Online
- View e-Book
- Other Authors
- Edelstein, Charles L
- Responsibility
- edited by Charles L. Edelstein
- Edition
- 2nd ed.
- Place of Publication
- Amsterdam, Netherlands
- Publisher
- Elsevier
- Date of Publication
- c2017
- Physical Description
- 1 online resource
- ISBN
- 9780128030141
- Subjects (MeSH)
- Kidney Diseases - diagnosis
- Biological Markers
- Subjects (LCSH)
- Kidney Diseases - diagnosis
- Biological Markers
- Kidneys - Diseases - Molecular diagnosis
- Biochemical markers
- Access
- Registration required for PDF access.
- Format
- e-Book
- Location
- Online
Biomarkers of kidney disease
https://libcat.nshealth.ca/en/permalink/provcat50417
Edelstein, Charles.
(2nd ed.)
--Philadelphia, PA:
Elsevier
, 2017.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Edelstein, Charles
- Edition
- 2nd ed.
- Place of Publication
- Philadelphia, PA
- Publisher
- Elsevier
- Date of Publication
- 2017
- ISBN
- 9780128030141
- Subjects (MeSH)
- Kidney Diseases - diagnosis
- Biological Markers
- Notes
- Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.
- Format
- e-Book
- Location
- Online
Biotargets of Cancer in Current Clinical Practice
https://libcat.nshealth.ca/en/permalink/provcat31016
Mauro Bologna, editor.
--New York, NY:
Humana Press
, c2012.
- Available Online
- View e-Book
- Location
- Online
Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (in…
- Available Online
- View e-Book
- Other Authors
- Bologna, Mauro
- Responsibility
- Mauro Bologna, editor
- Place of Publication
- New York, NY
- Publisher
- Humana Press
- Date of Publication
- c2012
- Physical Description
- 1 online resource (xvi, 563 p. : 100 ill., 57 ill. in color)
- Series Title
- Current clinical pathology
- ISBN
- 9781617796159
- Subjects (MeSH)
- Biological Markers
- Molecular Targeted Therapy
- Neoplasms - therapy
- Subjects (LCSH)
- Medical laboratories
- Oncology
- Pathology
- Abstract
- Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed.
- Contents
- Central Nervous System Tumors -- Head and Neck Tumors -- Thyroid Cancer -- Targeted Therapies for Non-Small Cell Lung Cancer -- Non-Hodgkin Lymphomas -- Leukemias -- Breast Cancer -- Esophago-Gastric Cancer -- Colorectal Cancer -- Hepatocellular Carcinoma -- Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma -- Bladder Cancer -- Biomarkers in Prostate cancer -- Ovarian Cancer -- Uterine Cancer: The Influence of Genetics and Environment on Cell Cycling Pathways in Cancer -- Biotargets in Sarcomas: The Past, Present and a Look into the Future -- Melanoma and other skin cancers -- Molecular pathology of cancer metastasis: suggestions for future therapy -- Current and future developments in cancer therapy research: miRNAs as new promising targets or tools.
- Format
- e-Book
- Location
- Online
Neurodegenerative diseases : clinical aspects, molecular genetics and biomarkers
https://libcat.nshealth.ca/en/permalink/provcat33732
Daniela Galimberti, Elio Scarpini, editors.
--London:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
This book gives an overview of the current knowledge on the most common neurodegenerative diseases, including Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and additional neurodegenerative diseases. Different aspects of each disease are reviewed, including clinical issues, treatments, basic discoveries (genetics and molecular biology), and translation of basic research into biomarkers for early diagnosis. In addition, emerging data indicate that neurodeg…
- Available Online
- View e-Book
- Other Authors
- Galimberti, Daniela
- Scarpini, E
- Responsibility
- Daniela Galimberti, Elio Scarpini, editors
- Place of Publication
- London
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xix, 253 pages)
- ISBN
- 9781447163800 (electronic bk.)
- 9781447163794
- Subjects (MeSH)
- Alzheimer Disease
- Neurodegenerative Diseases
- Biological Markers
- Subjects (LCSH)
- Nervous system - Degeneration
- Neurology
- Neurosciences
- Abstract
- This book gives an overview of the current knowledge on the most common neurodegenerative diseases, including Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and additional neurodegenerative diseases. Different aspects of each disease are reviewed, including clinical issues, treatments, basic discoveries (genetics and molecular biology), and translation of basic research into biomarkers for early diagnosis. In addition, emerging data indicate that neurodegeneration seems to also be present in classically non-degenerative disorders. Therefore, a chapter about overlapping mechanisms between dementias and psychiatric disorders is included, as well as a description of the role of neurodegeneration in multiple sclerosis. Neurodegenerative Diseases is aimed at clinicians, particularly those working in academic hospitals. This multidisciplinary book will also be of interest to basic researchers in medical fields.
- Contents
- Genetics and Epigenetics: Basic Concepts -- Alzheimer's Disease: Clinical Aspects and Treatments -- Autosomal Dominant Alzheimer's Disease: Underlying Causes -- Genetic Risk Factors for Alzheimer's Disease -- The Role of Cerebrovascular Disease in Cognitive Decline -- Nongenetic Risk Factors for Alzheimer's Disease -- Nongenetic Risk Factors for Alzheimer's Disease -- Frontotemporal Lobar Degeneration: Genetics and Clinical Phenotypes -- Alzheimer's Disease and Frontotemporal Lobar Degeneration: Mouse Models -- Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia -- Biomarkers for Alzheimer's Disease and Frontotemporal Lobar Degeneration: Imaging -- Amyotrophic Lateral Sclerosis: Genotypes and Phenotypes -- Uncommon Dementias -- Neurodevelopment Alterations, Neurodegeneration, and Immunoinflammatory Patterns in the Pathophysiology of Schizophrenia -- Neurodegeneration and Multiple Sclerosis.
- Format
- e-Book
- Location
- Online
Prevention of Bone Metastases
https://libcat.nshealth.ca/en/permalink/provcat31127
Markus Joerger, Michael Gnant, editors.
--Berlin, Heidelberg:
Springer
, c2012.
- Available Online
- View e-Book
- Location
- Online
Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with br…
- Available Online
- View e-Book
- Other Authors
- Joerger, Markus
- Gnant, Michael
- Responsibility
- Markus Joerger, Michael Gnant, editors
- Place of Publication
- Berlin, Heidelberg
- Publisher
- Springer
- Date of Publication
- c2012
- Physical Description
- 1 online resource (ix, 233 p. : 23 ill., 13 ill. in color)
- Series Vol.
- 192
- Series Title
- Recent results in cancer research
- ISBN
- 9783642218927
- Subjects (MeSH)
- Biological Markers
- Bone Neoplasms - prevention & control
- Bone Neoplasms - secondary
- Cytostatic Agents - therapeutic use
- Diphosphonates - therapeutic use
- Subjects (LCSH)
- Oncology
- Abstract
- Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with breast, lung, and prostate cancer and disease progression in cases of multiple myeloma. The combined use of bisphosphonates and cytostatics is also discussed, with a report on first clinical data. Further topics addressed include the significance of the bone microenvironment, special issues in the elderly patient, the use of bone turnover markers, and initial findings obtained with denosumab.
- Contents
- Preclinical Models that Illuminate the Bone Metastasis Cascade -- The Role of Bone Microenvironment, Vitamin D and Calcium -- Bisphosphonates: Prevention of Bone Metastases in Breast Cancer -- Bisphosphonates: Prevention of Bone Metastases in Lung Cancer -- Bisphosphonates: Prevention of Bone Metastases in Prostate Cancer -- Targeting Bone in Myeloma -- Combinations of Bisphosphonates and Classical Anticancer Drugs: A Preclinical Perspective -- Perspectives in the Elderly Patient: Benefits and Limits of Bisphosphonates and Denosumab -- Denosumab: First Data and Ongoing Studies on the Prevention of Bone Metastases -- Diagnostic and Prognostic Use of Bone Turnover Markers -- Osteolytic and Osteoblastic Bone Metastases: Two Extremes of the Same Spectrum?
- Format
- e-Book
- Location
- Online
Prostate cancer prevention
https://libcat.nshealth.ca/en/permalink/provcat33417
Jack Cuzick, Mangesh A. Thorat, editors.
--Heidelberg:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide r…
- Available Online
- View e-Book
- Other Authors
- Cuzick, J
- Thorat, Mangesh A
- Responsibility
- Jack Cuzick, Mangesh A. Thorat, editors
- Place of Publication
- Heidelberg
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (viii, 169 pages)
- Series Vol.
- v. 202
- Series Title
- Recent results in cancer research
- ISBN
- 9783642451959 (electronic bk.)
- 9783642451942
- Subjects (MeSH)
- Prostatic Neoplasms - prevention & control
- Anticarcinogenic Agents
- Chemoprevention
- Early Detection of Cancer
- Risk Factors
- Subjects (LCSH)
- Prostate - Cancer - Prevention
- Prostatic Neoplasms - prevention & control
- Risk Assessment
- Biological Markers
- Life Style
- Risk Factors
- Diet
- Chemoprevention
- Oncology
- Abstract
- Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.
- Contents
- The biology and natural history of prostate cancer: a short introduction -- Germline genetic variants associated with prostate cancer and potential relevance to clinical practice -- Lifestyle and dietary factors in prostate cancer prevention -- Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition -- Screening for prostate cancer: current status of ERSPC and screening-related issues -- Update of the prostate, lung, colorectal, and ovarian cancer screening trial -- ERSPC, PLCO studies and critique of Cochrane review 2013 -- Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies -- Phase III prostate cancer chemoprevention trials -- Risk adapted chemoprevention for prostate cancer: an option? -- Aspirin and prostate cancer prevention -- Chemoprevention of prostate cancer by isoflavonoids -- Lycopene for the prevention and treatment of prostate disease -- Chemoprevention of prostate cancer with the polyamine -- Synthesis inhibitor difluoromethylornithine -- Prostate cancer prevention: agent development strategies -- Prognostic value of a cell cycle progression score for men with prostate cancer -- Distinguishing indolent from aggressive prostate cancer -- Management of low risk and low PSA prostate cancer: long term results from the prostate cancer intervention versus observation trial.
- Format
- e-Book
- Location
- Online
